Physician profile
Brandy R Robinson
NPI 1861604225
$2,794.28
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $246 · 2021: $203 · 2022: $420 · 2023: $691 · 2024: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $466.89 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $463.89 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $371.06 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $193.03 | 2019-2020 | |
| Amgen INC. | $144.76 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $137.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.68 | 2019-2021 | |
| Allergan, INC. | $83.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $82.49 | 2019-2021 | |
| Amarin Pharma, INC. | $81.78 | 2019 | |
| Pfizer INC. | $74.66 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $64.09 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.26 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.92 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $50.16 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.79 | 2022-2023 | Freestyle Libre 2 |
| Sanofi Pasteur INC. | $32.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $29.61 | 2019 | |
| Aytu Biopharma, INC. | $26.72 | 2019 | |
| Lupin INC. | $26.61 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $25.44 | 2021 | |
| Eisai INC. | $23.82 | 2021 | |
| Axsome Therapeutics, INC. | $20.64 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $19.72 | 2023 | Quviviq |
| Dexcom, INC. | $19.51 | 2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $18.53 | 2019 | |
| Shire North American Group INC | $16.45 | 2019 | |
| Zyla Life Sciences, INC. | $16.13 | 2019 | |
| Glaxosmithkline, LLC. | $16.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.80 | 2020 | |
| Phadia US INC. | $13.28 | 2021 | |
| Genentech USA, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.